Published in Vaccine Weekly, August 18th, 1997
Such intracellular immunization of CD4 cells could be performed in vivo (by direct delivery to patients) or ex vivo (by removing CD4 cells from a patient, treating and expanding them in cell culture, and returning them to the patient).
"This retroviral vector should prove useful for the study of HIV infection events mediated by HIV-1 envelope glycoproteins, and for the targeting of CD4+ cells during gene therapy of AIDS," wrote Barbara S. Schnierle of the Institute for Experimental Cancer Research, Freiburg, Germany, and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.